2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Gene Editing, Profiling, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Study Population, Human, Adult, Elderly
PAPER

99 Single-cell genotyping and chromatin profiling of MDS-to-AML transformation reveals a leukemia-preceding chromatin state in mutant stem and progenitor cells

Felix A. Radtke, MD, Rabea Mecklenbrauck, MD2, Sven Turkalj, DPhil3, Batchimeg Usukhbayar, PhD4, Diego Pérez-Dones, PhD5, Niels Asger Jakobsen, DPhil6, Marlen Metzner, MSc7, Thomas Höfer, PhD8, Verena Körber, PhD9, Paresh Vyas, MD, PhD10
1 Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom, University of Oxford, Oxford, Oxfordshire, United Kingdom
2 Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom, University of Oxford, Oxford, Oxfordshire, United Kingdom
3 Harvard Medical School, Boston, Massachusetts, United States, University of Oxford, Oxford, Oxfordshire, United Kingdom
4 University of Oxford, Oxford, Oxfordshire, United Kingdom
5 University of Oxford, Oxford, Oxfordshire, United Kingdom
6 University of Oxford, Oxford, Oxfordshire, United Kingdom
7 University of Oxford, Oxford, Oxfordshire, United Kingdom
8 German Cancer Research Center, Heidelberg, Baden-Wurttemberg, Germany
9 University of Oxford, Oxford, Oxfordshire, United Kingdom
10 Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom, University of Oxford, Oxford, Oxfordshire, United Kingdom

Background. Myelodysplastic syndromes (MDS) are driven by evolving genetic clones, yet how somatic mutations reshape the epigenome of individual clones, leading to clonal advantage along the hematopoietic hierarchy, remains unclear. By jointly resolving chromatin accessibility, point mutations, and copy number alterations in the bone marrow of 5 longitudinally sampled MDS patients, 3 of whom progressed to acute myeloid leukemia (AML), we studied clone-intrinsic dynamics and asked whether patients who transform converge on shared chromatin programs.

Methods. We performed WGS (whole genome sequencing) at all timepoints to identify driver mutations followed by GTAC (scATAC-seq with concurrent genotyping, Turkalj et al, Cell Stem Cell 2023) and multiome (scATAC-seq and scRNA-seq) to measure open chromatin, RNA profiles and driver mutation status in hematopoietic stem and progenitor cells of 5 patients (2–4 timepoints each, sampled over 5–93 months; 3 with matched AML) at single-cell resolution. No patient received disease-modifying therapy during sampling. Clone initiation times were inferred from the reconstructed phylogenies by population genetics modelling (Körber et al, Nat Genet 2023). Cells were mapped to reference hematopoietic states, and mutation profiles were used to reconstruct clonal architecture along differentiation trajectories. Chromatin states were contrasted between clones, differentiation states and disease stages. Regulons were reconstructed with SCENIC+ in multiome, to which clone identity was transferred using copy-number alterations, single-molecule genotype evidence and GTAC-derived prior per differentiation state.

Results. Population-genetic modelling placed the emergence of the founding clone in childhood or adolescence, at a median patient age of 15 years (range, 8–19 years). Subsequent clonal branches emerged over progressively shorter intervals, consistent with acceleration of clonal evolution during disease progression, leading to the hypothesis that selection acts increasingly on rapidly dividing progenitors as compared to stem cells. In the 3 patients who progressed, a clone at or below 1% at first sampling rose to 55–88% of CD34+ cells at AML, indicative of strong clonal selection; the largest such expansion in a patient who did not progress reached 16%. AML samples showed distinct compartmental architectures (monocytic expansion in 1 patient; LMPP-dominant disease in 2). Despite ongoing genetic evolution, chromatin signatures of dominant clones in the final sample (AML in 3 patients, the last MDS sample in 2) were already enriched at baseline, suggesting that non-genetic changes predisposed further genetic evolution (GSEA normalized enrichment score 1.19–3.43, P = 0.045–1x10?5°; reproduced by an independent per-cell score: Cohen's d 0.23–2.46, one-sided P = 0.015–7x10?³²). Notably, in the 3 progressing patients, the signature was detected 1.5–8 years prior to AML diagnosis. Gene regulatory networks learned on matched multiome data showed concordant enhancer-level regulon activity and target-gene expression, including AP-1, KLF and ETS targets, enriched 1.3 to 4.6-fold at FDR < 0.05 in all 4 testable patients. Curated lineage-identity gene sets separated the two groups: in mutant HSC/MPP they were more accessible than in wild-type cells in both patients who did not transform, and less accessible in all 3 who did.

In the mutant clone at the earliest MDS timepoint, erythroid, monocytic, granulocytic and neutrophil-progenitor identity programs were more accessible than in wild-type cells in both patients who did not progress and less accessible in all 3 who did.

Summary. Combining genotyping and ATAC-seq at single cell resolution with regulatory networks trained on matched multiome data, we recover single-cell clonal trajectories between MDS and AML. Founding disease clones were inferred to arise early in life, at a median patient age of 15 years, with subsequent clonal evolution accelerating during progression. The regulatory identity of the dominant clone in leukemia appears to be partially acquired early during disease evolution, and differentiates patients subsequently transforming into AML from those who did not. These findings suggest that clone-resolved chromatin states provide functional information beyond genotype alone and may, after prospective validation, complement current approaches for transformation-risk assessment in MDS.

Felix A. Radtke, MD: No relevant conflicts of interest to declare.